FGFR1 and non-small cell lung carcinoma: The fact that C1632 suppresses the expression of LIN28 and blocks FGFR1 signalling supports the idea that it has the potential to serve as an anti‐NSCLC drug (Figure 2D‐G, Figures S3 and S4).